Injective slips 13.05% as downside momentum accelerates after resistance rejection
Injective (INJ) is trading at $3.45 after a sharp daily drop of 13.05%. The token remains well below the MA-20 ($4.78), MA-50 ($4.83), and MA-200 ($9.35), underscoring continued downside pressure and confirming a firm bearish bias across all monitored timeframes.
5.27
5.84
Highlights
- INJ is trading at $3.45, significantly below the MA-20 ($4.78), MA-50 ($4.83), and MA-200 ($9.35), indicating persistent downside pressure.
- Bearish momentum dominates as MACD and ADX confirm selling strength, with RSI at 32.71 and Stochastic RSI at 0.00 signaling oversold conditions.
- Next five sessions’ price range is projected at $3.34–$3.96, with over an 80% probability of further decline unless a sustained rebound above $3.96 occurs.
Bearish momentum persists as oversold signals reach extremes
Technically, INJ faces the nearest dynamic resistance at the Ichimoku Kijun level of $4.91. Momentum indicators point to further weakness, with the MACD and ADX both affirming strong selling, while the oversold readings from the RSI (32.71), Stochastic RSI (0.00), and CCI (–134.45) indicate overstretched conditions. Bull/Bear Power is negative (–0.38) and the Awesome Oscillator confirms persistent downside momentum. INJ is currently hovering near session lows, reflecting high volatility and unified bearish signals across price action and momentum metrics.
Downside risk dominates as consolidation expected within current range
Over the next five trading days, INJ is likely to consolidate within a typical volatility band of $3.34 – $3.96, given current volatility. There is a strong probability (over 80%) of continued decline, and any meaningful rebound is less likely unless the price rises above $3.96 — this would target resistance at $4.91. If INJ closes below $3.34, a new leg lower is likely to develop. The baseline scenario is for further choppy trading in the current range with downside risk prevailing.
Previously it was reported that Injective (INJ) continues to show strong bearish momentum, trading below key moving averages and encountering dynamic resistance near $4.91. Technical indicators including MACD, ADX, and multiple oversold signals confirm persistent selling pressure, leaving the asset vulnerable to further declines absent a significant reversal.
Latest Injective News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
